132 related articles for article (PubMed ID: 15847987)
1. A novel water-soluble cyclosporine A prodrug: ocular tolerance and in vivo kinetics.
Lallemand F; Furrer P; Felt-Baeyens O; Gex-Fabry M; Dumont JM; Besseghir K; Gurny R
Int J Pharm; 2005 May; 295(1-2):7-14. PubMed ID: 15847987
[TBL] [Abstract][Full Text] [Related]
2. In vivo characterisation of a novel water-soluble Cyclosporine A prodrug for the treatment of dry eye disease.
Rodriguez-Aller M; Kaufmann B; Guillarme D; Stella C; Furrer P; Rudaz S; El Zaoui I; Valamanesh F; Di Tommaso C; Behar-Cohen F; Veuthey JL; Gurny R
Eur J Pharm Biopharm; 2012 Apr; 80(3):544-52. PubMed ID: 22155591
[TBL] [Abstract][Full Text] [Related]
3. Conversion of cyclosporine A prodrugs in human tears vs rabbits tears.
Lallemand F; Felt-Baeyens O; Rudaz S; Hamel AR; Hubler F; Wenger R; Mutter M; Besseghir K; Gurny R
Eur J Pharm Biopharm; 2005 Jan; 59(1):51-6. PubMed ID: 15567301
[TBL] [Abstract][Full Text] [Related]
4. A water-soluble prodrug of cyclosporine A for ocular application: a stability study.
Lallemand F; Perottet P; Felt-Baeyens O; Kloeti W; Philippoz F; Marfurt J; Besseghir K; Gurny R
Eur J Pharm Sci; 2005 Sep; 26(1):124-9. PubMed ID: 15978789
[TBL] [Abstract][Full Text] [Related]
5. In vivo distribution and ex vivo permeation of cyclosporine A prodrug aqueous formulations for ocular application.
Rodriguez-Aller M; Guillarme D; El Sanharawi M; Behar-Cohen F; Veuthey JL; Gurny R
J Control Release; 2013 Aug; 170(1):153-9. PubMed ID: 23648835
[TBL] [Abstract][Full Text] [Related]
6. Biological conversion of a water-soluble prodrug of cyclosporine A.
Lallemand F; Varesio E; Felt-Baeyens O; Bossy L; Hopfgartner G; Gurny R
Eur J Pharm Biopharm; 2007 Sep; 67(2):555-61. PubMed ID: 17475453
[TBL] [Abstract][Full Text] [Related]
7. Novel microemulsion in situ electrolyte-triggered gelling system for ophthalmic delivery of lipophilic cyclosporine A: in vitro and in vivo results.
Gan L; Gan Y; Zhu C; Zhang X; Zhu J
Int J Pharm; 2009 Jan; 365(1-2):143-9. PubMed ID: 18773948
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of a topical cyclosporine A prodrug on corneal graft rejection in rats.
Bourges JL; Lallemand F; Agla E; Besseghir K; Dumont JM; BenEzra D; Gurny R; Behar-Cohen F
Mol Vis; 2006 Dec; 12():1461-6. PubMed ID: 17167400
[TBL] [Abstract][Full Text] [Related]
9. Ocular distribution of cyclosporin A (Sandimmun) following systemic and topical administration to rabbits.
Vernillet L; Lundh RL; Acezat-Mispelter F; Goizel C; Humbert H; Pouliquen Y
Eur J Drug Metab Pharmacokinet; 1991; Spec No 3():150-8. PubMed ID: 1820870
[TBL] [Abstract][Full Text] [Related]
10. Semifluorinated alkanes as a liquid drug carrier system for topical ocular drug delivery.
Dutescu RM; Panfil C; Merkel OM; Schrage N
Eur J Pharm Biopharm; 2014 Sep; 88(1):123-8. PubMed ID: 24844949
[TBL] [Abstract][Full Text] [Related]
11. Development of a novel ophthalmic ciclosporin A-loaded nanosuspension using top-down media milling methods.
Kim JH; Jang SW; Han SD; Hwang HD; Choi HG
Pharmazie; 2011 Jul; 66(7):491-5. PubMed ID: 21812323
[TBL] [Abstract][Full Text] [Related]
12. Distribution of cyclosporine A in ocular tissues after topical administration of cyclosporine A cationic emulsions to pigmented rabbits.
Daull P; Lallemand F; Philips B; Lambert G; Buggage R; Garrigue JS
Cornea; 2013 Mar; 32(3):345-54. PubMed ID: 23023401
[TBL] [Abstract][Full Text] [Related]
13. Water-soluble prodrugs of cyclosporine A with tailored conversion rates.
Hamel AR; Hubler F; Mutter M
J Pept Res; 2005 Mar; 65(3):364-74. PubMed ID: 15787967
[TBL] [Abstract][Full Text] [Related]
14. A novel cyclosporin a aqueous formulation for dry eye treatment: in vitro and in vivo evaluation.
Di Tommaso C; Valamanesh F; Miller F; Furrer P; Rodriguez-Aller M; Behar-Cohen F; Gurny R; Möller M
Invest Ophthalmol Vis Sci; 2012 Apr; 53(4):2292-9. PubMed ID: 22427552
[TBL] [Abstract][Full Text] [Related]
15. Cyclosporine a-loaded solid lipid nanoparticles: ocular tolerance and in vivo drug release in rabbit eyes.
Gökçe EH; Sandri G; Eğrilmez S; Bonferoni MC; Güneri T; Caramella C
Curr Eye Res; 2009 Nov; 34(11):996-1003. PubMed ID: 19958116
[TBL] [Abstract][Full Text] [Related]
16. Thiolated nanostructured lipid carriers as a potential ocular drug delivery system for cyclosporine A: Improving in vivo ocular distribution.
Shen J; Deng Y; Jin X; Ping Q; Su Z; Li L
Int J Pharm; 2010 Dec; 402(1-2):248-53. PubMed ID: 20934499
[TBL] [Abstract][Full Text] [Related]
17. Preclinical evaluation of a novel episcleral cyclosporine implant for ocular graft-versus-host disease.
Kim H; Csaky KG; Gilger BC; Dunn JP; Lee SS; Tremblay M; de Monasterio F; Tansey G; Yuan P; Bungay PM; Lutz RJ; Robinson MR
Invest Ophthalmol Vis Sci; 2005 Feb; 46(2):655-62. PubMed ID: 15671296
[TBL] [Abstract][Full Text] [Related]
18. [Intraocular implantation of cyclosporine A drug delivery system in the treatment of experimental uveitis].
Dong XG; Xu YM; Yuan GQ; Shi WY; Xie LX; Wang SG
Zhonghua Yan Ke Za Zhi; 2005 Jul; 41(7):636-41. PubMed ID: 16080900
[TBL] [Abstract][Full Text] [Related]
19. [Drug release and biocompatibility of cyclosporine A drug delivery system implanting into the anterior chamber].
Liu ZS; Xie LX; Shi WY; Li SW; Cai Q; Bei JZ; Wang SG
Zhonghua Yan Ke Za Zhi; 2004 Feb; 40(2):108-12. PubMed ID: 15059564
[TBL] [Abstract][Full Text] [Related]
20. Ocular biocompatibility of novel Cyclosporin A formulations based on methoxy poly(ethylene glycol)-hexylsubstituted poly(lactide) micelle carriers.
Di Tommaso C; Torriglia A; Furrer P; Behar-Cohen F; Gurny R; Möller M
Int J Pharm; 2011 Sep; 416(2):515-24. PubMed ID: 21219997
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
